LaNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADC

Research & Development

L aNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADC

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive licence agreement for a preclinical stage antibody drug conjugate (ADC).

LM-305 targets G protein-coupled receptor, class C, group 5, member D (GPRC5D). It consists of an anti-GRPC5D monoclonal antibody, a protease-degradable linker and a cytotoxic payload monomethyl auristatin E (MMAE). It is indicated for use in patients with multiple myeloma.

Within the agreement, AstraZeneca will be granted full exclusive global licence to research, develop and commercialise LM-305. LaNova will be eligible for upfront and near-term payments of up to $55m, as well as additional development and commercial milestone payments of up to $545m and tiered royalties on net sales.

Dr Crystal Qin, founder, chairman and CEO of LaNova Medicines commented: “LaNova Medicines has a strong focus on discovering and developing innovative medicines in the ADC and immuno-oncology fields. We’re excited to reach this agreement with AstraZeneca. With the potential to become a first-in-class GPRC5D-directed ADC for multiple myeloma, LM-305 exemplifies our innovative and robust platform for ADC development. This agreement is further recognition of our exceptional pipeline assets and R&D capabilities. We are confident that AstraZeneca is the ideal company to advance LM-305 for the betterment of patients globally.”

Nina Shah, global head of multiple myeloma, Haematology R&D at AstraZeneca, said: “We are pleased to have the opportunity to advance the development of LM-305, a novel GPRC5D-targeting ADC, as a potential new treatment option for relapsed/refractory multiple myeloma. LM-305 advances our leadership in ADCs and enriches our growing Haematology pipeline, helping us deliver against our broader ambition to transform clinical outcomes for patients living with blood cancers.”

Treatment programme for CVD to be developed as part of partnership between Novartis and Ionis

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and licence agreement with Novartis, aiming to discover, develop and commercialise a novel medicine for patients with lipoprotein(a) or lp(a)-driven cardiovascular disease (CVD).

Biogen plans to acquire Reata Pharmaceuticals for $7.3bn

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for approximately $7.3bn, or $172.50 per share.

Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s Alexion

Alexion has announced that it has entered a definitive purchase and licence agreement with Pfizer.

Eli Lilly shares plans to acquire Versanis Bio for $1.9bn

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focusing on the development of new medicines to treat cardiometabolic diseases.

Lonza to acquire Synaffix to strengthen ADC development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza, has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

Treatment programme for CVD to be developed as part of partnership between Novartis and Ionis

Biogen plans to acquire Reata Pharmaceuticals for $7.3bn

Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s Alexion

Eli Lilly shares plans to acquire Versanis Bio for $1.9bn

Lonza to acquire Synaffix to strengthen ADC development

Pharmafocus

Categories

Social Footprints